Beamtree reports a record year of financial and commercial growth in FY21

Servicing customers in more than 1,000 locations, including 700 public and private hospitals, and operating in more than 22 countries across 4 continents Beamtree (formerly PKS Holdings) produced its strongest revenue performance to date with 20% year-on-year growth pro forma and 15% increase in annual recurring revenue for FY21.


Group revenue grew 103% on a statutory basis. Recurrent revenues were at 78% of operating revenues – significantly ahead of forecast expectations.

Separately, the company has seen 83% growth in number of employees, the establishment of a UK office to drive international business development and client retention exceeding expectations. Renewals for our AI pathology services were 100%.

Growth has been driven by major new client wins for PICQ® (data quality) and RISQ™  (benchmarking services) products, international expansion – winning our first national data quality audit in Kingdom of Saudi Arabia (TCV $2m), following success in Ireland and Singapore – and the roll-out of our RippleDown® product into pathology services in several new countries. Investment in product, technology and go-to-market capacity has delivered rapid service enhancement and improved volume of direct sales.

See the FY21 Annual Report

See other stories

  • Beamtree acquires AI pioneer

    Beamtree announced the acquisition of Ainsoff Ltd in line with the company’s strategy to expand the Beamtree health service offering.

    Read more
  • Beamtree partners with USYD data science team

    Beamtree and the University of Sydney have announced their plans to ensure health data research is accelerated to improve the health of all Australians.

    Read more
  • Beamtree Launches

    Beamtree… A fresh identity for a company dedicated to better patient data. What's a Beamtree?

    Read more